Treatment with an anti-glucocorticoid-induced TNF receptor (GITR) monoclonal antibody (mAb) can inhibit Treg function and tumor infiltration by downregulating CCR5 expression, resulting in the suppression of subcutaneous pancreatic tumor growth in a murine model. The gene discussed is CCR5; the disease is neoplasm.